SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.

SAN DIEGO, Aug. 11, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study

New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions

Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment

Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study

New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions

Translational data further elucidate pelareorep's mechanism of action and ability to prime the tumor microenvironment for treatment

Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities

SAN DIEGO, Aug. 8, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily delisted from the Toronto Stock Exchange ("TSX") at the close of markets on August 22, 2025, pursuant to the Company's application for voluntary delisting and the satisfaction of the conditions to delist from the TSX. The delisting from the TSX will not affect the Company's listing on the Nasdaq.

SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily delisted from the Toronto Stock Exchange ("TSX") at the close of markets on August 22, 2025, pursuant to the Company's application for voluntary delisting and the satisfaction of the conditions to delist from the TSX. The delisting from the TSX will not affect the Company's listing on the Nasdaq.

Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder value and partnership opportunities

SAN DIEGO and CALGARY, AB, July 29, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced it has initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) for a potential registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Assuming discussions with the FDA go as expected, the Company expects to commence study start-up activities before the end of 2025.

Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder value and partnership opportunities

SAN DIEGO and CALGARY, AB, July 29, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced it has initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) for a potential registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Assuming discussions with the FDA go as expected, the Company expects to commence study start-up activities before the end of 2025.

SAN DIEGO and CALGARY, AB, July 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion. A replay of the full conversation can be found by clicking here.

SAN DIEGO and CALGARY, AB, July 23, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion. A replay of the full conversation can be found by clicking here.

SAN DIEGO and CALGARY, AB, July 22, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "ONCY." 

SAN DIEGO and CALGARY, AB, July 22, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "ONCY." 

Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment

Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors

Results reinforce pelareorep's ability to turn cold tumors hot, paving the way for registration-enabling trials

SAN DIEGO and CALGARY, AB, July 16, 2025 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, summarized its biomarker and translational data for pelareorep, the Company's systemically delivered oncolytic virus. The data support pelareorep's mechanism of action and further strengthen the unique biological rationale and therapeutic potential for pelareorep as a platform immunotherapeutic. These include its ability to replicate in cancer cells, activate immune pathways, and drive T cell expansion and tumor infiltration in immunotherapy-resistant cancers.

Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment

Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors

Results reinforce pelareorep's ability to turn cold tumors hot, paving the way for registration-enabling trials

SAN DIEGO and CALGARY, AB, July 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, summarized its biomarker and translational data for pelareorep, the Company's systemically delivered oncolytic virus. The data support pelareorep's mechanism of action and further strengthen the unique biological rationale and therapeutic potential for pelareorep as a platform immunotherapeutic. These include its ability to replicate in cancer cells, activate immune pathways, and drive T cell expansion and tumor infiltration in immunotherapy-resistant cancers.

KOL webinar to take place on July 22, 2025, at 1:00 p.m. ET

SAN DIEGO and CALGARY, AB, July 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, announced that it will host a key opinion leader (KOL) webinar to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers. The webinar will take place on Tuesday, July 22, 2025, at 1:00 p.m. ET.

KOL webinar to take place on July 22, 2025, at 1:00 p.m. ET

SAN DIEGO and CALGARY, AB, July 10, 2025 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, announced that it will host a key opinion leader (KOL) webinar to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers. The webinar will take place on Tuesday, July 22, 2025, at 1:00 p.m. ET.

Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark

Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication

Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile

SAN DIEGO and CALGARY, AB, July 8, 2025 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced a strategic update highlighting its compelling clinical data from two tumor types and outlining a sharpened focus on advancing pelareorep, the Company's intravenously delivered oncolytic virus immunotherapy, into registration-enabling studies.

Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark

Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication

Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile

SAN DIEGO and CALGARY, AB, July 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced a strategic update highlighting its compelling clinical data from two tumor types and outlining a sharpened focus on advancing pelareorep, the Company's intravenously delivered oncolytic virus immunotherapy, into registration-enabling studies.

SAN DIEGO and CALGARY, Alberta, June 30, 2025 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer.

Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will also be directly involved with developing corporate, clinical and regulatory strategies. Among his key priorities will be optimizing the value of the Company's expansive suite of promising clinical data for pelareorep in multiple tumor types, including pancreatic, breast, and anal cancers.

SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer.

Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will also be directly involved with developing corporate, clinical and regulatory strategies. Among his key priorities will be optimizing the value of the Company's expansive suite of promising clinical data for pelareorep in multiple tumor types, including pancreatic, breast, and anal cancers.